Skip to main content

Table 6 Five- and 10-year cumulative incidence of distant metastases of breast cancer patients with local R0 resection by age, tumor characteristics and provided recommended treatments

From: Risk of loco-regional recurrence and distant metastases of patients with invasive breast cancer up to ten years after diagnosis – results from a registry-based study from Germany

Category/treatment

 

N

5-year CI

10-year CI

p-value

 

PE

95% CI

PE

95% CI

Overall

 

5311

7.2

[6.5, 7.9]

11.3

[10.4, 12.3]

 

Age

<  70 years

3714

7.8

[7.0, 8.7]

12.5

[11.4, 13.7]

< 0.001

 

≥ 70 years

1597

5.8

[4.7, 7.0]

8.6

[7.2, 10.2]

Clinical stage

T1/2N0

2918

3.6

[3.0, 4.4]

6.0

[5.1, 7.0]

< 0.001

 

T1/2N+

1613

10.8

[9.4, 12.4]

17.5

[15.6, 19.7]

T3/4N0

124

11.3

[6.9, 18.6]

16.6

[10.9, 25.4]

T3/4N+

409

19.6

[16.1, 23.8]

27.3

[23.0, 32.4]

missing

247

3.3

[1.6, 6.5]

4.3

[2.3, 7.9]

Morphology

invasive ductal

3690

7.6

[6.8, 8.5]

11.5

[10.4, 12.7]

0.085

 

invasive lobular

758

6.6

[5.1, 8.7]

12.4

[10.1, 15.4]

mixed type

459

6.3

[4.5, 9.0]

11.3

[8.6, 15.0]

other

404

5.3

[3.5, 8.0]

7.0

[4.8, 10.2]

Histopathologic grade

1

447

1.4

[0.6, 3.0]

3.9

[2.3, 6.6]

< 0.001

 

2

3332

5.8

[5.0, 6.6]

9.8

[8.7, 10.9]

3/4

1497

12.1

[10.5, 13.8]

17.0

[15.1, 19.1]

missing

35

9.0

[3.0, 26.9]

9.0

[3.0, 26.9]

HR expression

positive a

4132

5.6

[5.0, 6.4]

10.0

[9.0, 11.0]

< 0.001

 

negative

775

15.9

[13.5, 18.7]

19.0

[16.4, 22.1]

missing

404

6.3

[4.3, 9.1]

9.8

[7.0, 13.8]

HER2/neu expression

positive b

972

9.1

[7.4, 11.1]

15.1

[12.8, 17.8]

0.001

 

negative

2941

6.6

[5.7, 7.5]

9.8

[8.7, 11.0]

missing

1398

7.2

[6.0, 8.7]

11.6

[9.9, 13.5]

Subtype based on immunohistochemical surrogates

’HR positive‘

4132

5.6

[5.0, 6.4]

10.0

[9.0, 11.0]

< 0.001

 

‚HER2/neu positive‘c

234

15.9

[11.8, 21.4]

19.4

[14.7, 25.5]

‚triple negative‘d

376

16.3

[12.9, 20.5]

18.7

[15.0, 23.2]

missing

569

8.9

[6.8, 11.5]

12.6

[10.0, 15.9]

BCS

T1/2N0

198

3.1

[1.4, 6.7]

4.4

[2.2, 8.7]

BCS + RT

T1/2N0

2114

3.0

[2.4, 3.9]

5.4

[4.5, 6.6]

Mastectomy

T1/2N0

606

5.8

[4.2, 8.0]

8.2

[6.2, 10.8]

(BCS + RT or mastectomy) + HT

T1/2N0 HR positive a

1749

2.7

[2.0, 3.6]

5.2

[4.2, 6.5]

(BCS + RT or mastectomy) + CT

T1/2N0 HR negative

277

7.9

[5.3, 11.9]

9.2

[6.3, 13.4]

(BCS + RT or mastectomy) + HT (if HR positive) + CT (if HR negative) + TT

T1/2N0 HER2/neu positive

73

2.7

[0.7, 10.9]

2.7

[0.7, 10.9]

(BCS or mastectomy) + RT + CT + HT

T1/2N+ HR positive a

554

8.6

[6.5, 11.3]

15.4

[12.2, 19.3]

(BCS or mastectomy) + RT + CT

T1/2N+ HR negative

156

23.2

[17.4, 31.0]

30.7

[23.9, 39.4]

(BCS or mastectomy) + RT + CT + HT (if HR positive) + TT

T1/2N+ HER2/neu positive

51

13.7

[6.8, 27.5]

16.0

[8.4, 30.5]

MAST + RT + CT + HT

T3/4 HR positive a

88

14.8

[8.9, 24.5]

24.1

[15.8, 36.8]

MAST + RT + CT

T3/4 HR negative

50

40.0

[28.3, 56.5]

40.0

[28.3, 56.5]

  1. The sample includes female patients with primary invasive breast cancer (ICD-10 code: C50) without distant metastases from Saarland diagnosed between 1999 and 2009. CI cumulative incidence, PE point estimate of CI, 95% CI 95% confidence interval of PE, T, N T and N category of TNM classification, HR hormone receptor, HER2/neu human epidermal growth factor receptor 2, BCS breast conserving surgery, RT radiotherapy, CT chemotherapy, HT hormonal (anti-estrogen) treatment, TT targeted treatment (trastuzumab). aincludes tumors with mixed HR expression (either estrogen or progesterone receptor positive), bincludes tumors with borderline expression of HER2/neu, cHER2/neu positive, but HR negative, dboth HR negative and HER2/neu negative
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us